Company Description
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients.
The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products.
It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International.
Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
| Country | Ireland |
| Founded | 1987 |
| IPO Date | Jul 16, 1991 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 2,050 |
| CEO | Blair Jackson |
Contact Details
Address: Connaught House, 1 Burlington Road Dublin, D04 C5Y6 Ireland | |
| Phone | 353 1 772 8000 |
| Website | alkermes.com |
Stock Details
| Ticker Symbol | ALKS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001520262 |
| CUSIP Number | G01767105 |
| ISIN Number | IE00B56GVS15 |
| Employer ID | 98-1007018 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David Joseph Gaffin J.D. | Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary |
| Dr. Craig C. Hopkinson M.D. | Executive Vice President of Research and Development and Chief Medical Officer |
| Christian Todd Nichols | Senior Vice President and Chief Commercial Officer |
| Samuel J. Parisi | Interim Principal Accounting Officer and Vice President of Finance |
| Tom Skoff | SVice President and Chief Information Officer |
| Sandra Coombs | Senior Vice President of Corporate Affairs and Investor Relations |
| Stephen Schiavo | Senior Vice President and Chief Human Resources Officer |
| Peter Norman | SVice President of Policy, Government and Community Relations |
| Declan O'Connor | Senior Vice President of Operations and Environment, Health and Safety |
| Grace Doyle | Senior Vice President of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 3, 2026 | 144 | Filing |
| Aug 3, 2026 | 144 | Filing |
| Aug 3, 2026 | 144 | Filing |
| Aug 3, 2026 | 8-K/A | [Amend] Current report |
| Jul 28, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 28, 2026 | 10-Q | Quarterly Report |
| Jul 28, 2026 | 8-K | Current Report |
| Jul 8, 2026 | 8-K | Current Report |
| Jul 6, 2026 | 144 | Filing |
| Jul 1, 2026 | 144 | Filing |